acalabrutinib - Profile

What are the generic drug sources for acalabrutinib and what is the scope of patent protection?

Acalabrutinib is the generic ingredient in one branded drug marketed by Astrazeneca and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acalabrutinib has two hundred and twenty-five patent family members in fifty-one countries.

There are two tentative approvals for this compound.

Summary for acalabrutinib

International Patents:	225
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for acalabrutinib

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for acalabrutinib

Constraining patent/regulatory exclusivity:

9,290,504

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for ACALABRUTINIB

Applicant	Application No.	Strength	Dosage Form
		100MG	CAPSULE;ORAL
		100MG	CAPSULE

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ACALABRUTINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CALQUENCE	Capsules	acalabrutinib	100 mg	210259	5	2021-11-01

US Patents and Regulatory Information for acalabrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes	9,796,721		Y	Y
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes	10,272,083
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes	10,167,291		Y
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes	10,239,883
Astrazeneca	CALQUENCE	acalabrutinib	CAPSULE;ORAL	210259-001	Oct 31, 2017		RX	Yes	Yes	11,166,951

EU/EMA Drug Approvals for acalabrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Calquence	acalabrutinib	EMEA/H/C/005299Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Authorised	no	no	no	2020-11-05

International Patents for acalabrutinib

Country	Patent Number	Title	Estimated Expiration
Australia	2016286548
Australia	2020277123
Australia	2022291635
Canada	2991096
Chile	2017003445

Supplementary Protection Certificates for acalabrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3179991	LUC50025	Luxembourg		PRODUCT NAME: CALQUENCE - ACALABRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/20/1479 20250602
2734522	2021016	Norway		PRODUCT NAME: AKALABRUTINIB; REG. NO/DATE: EU/1/20/1479 20201111
2734522	122021000020	Germany		PRODUCT NAME: ACALABRUTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/20/1479 20201105
3179991	CA 2025 00039	Denmark		PRODUCT NAME: ACALABRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, I KOMBINATION MED VENETOCLAX MED ELLER UDEN OBINOTUZUMAB; REG. NO/DATE: EU/1/20/1479 20250603
2734522	PA2021004	Lithuania		PRODUCT NAME: AKALABRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1479/001-EU/1/20/1479/002 20201105

Acalabrutinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Acalabrutinib, marketed as Calquence®, is a Bruton’s tyrosine kinase (BTK) inhibitor approved primarily for treating certain hematologic malignancies, notably chronic lymphocytic leukemia (CLL). Developed by AstraZeneca, it competes within a crowded oncology landscape driven by increasing cancer prevalence, evolving treatment protocols, and expanding indications. This analysis assesses current market dynamics, projection of sales trajectories, competitive landscape, regulatory developments, and investment opportunities, providing a comprehensive outlook for stakeholders.

---

1. Investment Scenario Overview

Aspect	Key Details
Market Cap (2023)	~$200 billion (AstraZeneca, AZN)
Existing Revenue (2022)	~$670 million (Calquence sales, AZN)
Projected CAGR (2021-2028)	Approx. 18-20% (Source: EvaluatePharma)
Market Penetration	High in US, expanding globally
Pipeline Status	Ongoing trials for additional indications (e.g., mantle cell lymphoma, Waldenström’s macroglobulinemia)
Investment Outlook	Positive, driven by expansion opportunities but tempered by competitive pressures

2. Market Dynamics

a. Market Size and Growth Potential

• Hematologic Malignancies Demand
  The global CLL market alone was valued at approximately $4.5 billion in 2022 and expected to grow at 8-10%. The broader BTK inhibitor space is projected to reach over $10 billion by 2028, incorporating new indications and line extensions.

• Key Drivers

  • Rising incidence of CLL and other B-cell malignancies (e.g., mantle cell lymphoma)
  • Shift towards targeted oral therapies over traditional chemotherapies
  • Growing preference for combination regimens incorporating BTK inhibitors

• Market Expansion Areas

  • Europe and Asia-Pacific: Regulatory approvals and increasing healthcare expenditure
  • Earlier-line Treatments: Shift from relapsed/refractory to front-line therapies in clinical practice guidelines

b. Competitive Landscape and Positioning

Competitors	Key Drugs	Market Share (2022)	Notable Features
Ibrutinib (Imbruvica, AbbVie/Johnson & Johnson)	Ibrutinib	~50% of BTK inhibitor sales	First-in-class, broader indications, adverse effect profile
Acalabrutinib (Calquence, AZN)	Acalabrutinib	~15-20%	More selective, fewer off-target effects, approved for multiple indications
Zanubrutinib (Brukinsa, BeiGene)	Zanubrutinib	Emerging	Similar selectivity profile, expanding indications

Key Observation: Acalabrutinib’s differentiation hinges on improved tolerability, which supports its positioning, especially for patients intolerant to ibrutinib.

c. Regulatory and Clinical Development Landscape

• FDA Approvals (2019): CLL, mantle cell lymphoma (MCL), relapsed small lymphocytic lymphoma

• EMA Approvals: Similar indications; expanded to other territories subsequently

• Pipeline and Trials

  • Additional Indications: Waldenström macroglobulinemia, marginal zone lymphoma, other B-cell lymphomas
  • Combination Trials: With anti-CD20 monoclonal antibodies and other targeted therapies

Implication: Accelerating approvals and expanding indications are expected to enhance revenue streams.

3. Financial Trajectory Projections

a. Revenue Forecasts

Year	Estimated Sales (USD millions)	Growth Drivers	Assumptions
2023	~$1,000	Ongoing global expansion	Maintaining market share, new approvals
2024	~$1,380	Expanded indications	Additional launches in MCL, WM
2025	~$1,800	Broader use in earlier lines	Inclusion in combination regimens
2026-2028	$2,500+	Penetration in Asia, pipeline success	Launches in new indications, increased adoption

b. Cost Structure and Profit Margin

• R&D Investment: Significant (~17% of revenue, AZN data)
• Manufacturing & Distribution: High margins (~70+%) due to oral formulation
• Pricing Policies: Premium pricing in developed markets (~$150,000/year per patient)

c. Risks and Opportunities

Risks	Opportunities
Competitive pressures	New BTK inhibitors with better profiles
Market access hurdles	Expansion into emerging markets
Regulatory delays	Accelerated approvals in additional indications

4. Comparative Analysis of BTK Inhibitors

Attribute	Ibrutinib	Acalabrutinib	Zanubrutinib
Selectivity	Moderate	High	High
Adverse Effects	BB bleeding, atrial fibrillation	Fewer off-target effects	Similar to acalabrutinib
Indications	Multiple B-cell malignancies	Similar, with potentially better tolerability	Similar
Market Share (2022)	~50%	~15-20%	Growing

5. Regulatory Policies and Reimbursement Environment

• US: CMS and private insurers favor targeted therapies; favorable reimbursement can accelerate adoption.
• EU: Pricing negotiations are more stringent; patent protection and EUR patent laws impact timing.
• Emerging Markets: Price flexibility and local partnerships critical for growth.

---

6. Strategic Investment Considerations

Factor	Implication
Pipeline Strength	Diversification reduces dependency on a single indication
Market Positioning	Differentiation via safety profile supports premium pricing
Patent Life	Patent expiration (~2030) necessitates lifecycle extension strategies
Partnerships	Collaborations with biotech to access new therapies
Regulatory Trends	Focus on accelerated pathways (EUA, conditional approvals)

---

Key Comparisons

Aspect	Acalabrutinib	Ibrutinib	Zanubrutinib
Selectivity	Higher	Moderate	High
Adverse Event Profile	Better	Worse	Comparable to acalabrutinib
Indication Approval Scope	Broadening	Broad	Broadening
Market Share (2022)	15-20%	~50%	Growing

---

FAQs

Q1: What are the main drivers behind acalabrutinib’s growth?
The primary drivers include its improved safety profile over first-generation BTK inhibitors, expanding indications like mantle cell lymphoma and Waldenström’s macroglobulinemia, and global regulatory approvals.

Q2: How does acalabrutinib compare financially to competitors?
While currently generating lower revenues than ibrutinib, acalabrutinib’s premium safety profile supports higher pricing and longer-term market expansion, with projected revenues surpassing $2.5 billion by 2028.

Q3: What are the main risks for investors in acalabrutinib?
Risks include market competition, patent cliffs, regulatory delays, and potential adverse safety findings, which could limit adoption or necessitate price reductions.

Q4: How do regulatory policies affect acalabrutinib’s sales?
Regulatory approvals in major markets like the US and EU, along with positive reimbursement policies, are critical for sales growth. Emerging markets offer expansion opportunities but require strategic pricing and partnerships.

Q5: What pipeline developments could influence acalabrutinib’s long-term prospects?
Ongoing trials for additional indications, combination therapies, and head-to-head studies can enhance its positioning and unlock new revenue streams, supporting long-term growth.

---

Key Takeaways

• Market Potential: The global BTK inhibitor market is projected to grow at an 18-20% CAGR through 2028, driven by increasing disease prevalence and expanding indications.
• Competitive Position: Acalabrutinib’s improved safety profile allows it to maintain a competitive edge over first-generation BTK inhibitors like ibrutinib, particularly in higher-risk populations.
• Revenue Trajectory: Estimated to reach over $2.5 billion annually by 2028 with continued pipeline development and market penetration.
• Risks and Challenges: Strong competition, patent expiry concerns, and regulatory hurdles warrant careful monitoring.
• Investment Outlook: Acalabrutinib represents a promising opportunity within the hematologic oncology segment, supported by its differentiated profile and expanding indications.

---

References

[1] EvaluatePharma. "BTK inhibitors market report," 2022.
[2] AstraZeneca. "Calquence® (acalabrutinib) Prescribing Information," 2022.
[3] Grand View Research. "Hematologic Malignancies Market Size & Trends," 2023.
[4] ClinicalTrials.gov. "Ongoing Trials for Acalabrutinib," 2023.
[5] IQVIA. "Global Oncology Market Insights," 2022.